Korea's Celltrion Banks On Increasing Profits Resulting From New Focus On Biosimilars
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Biopharmaceutical firm Celltrion posted a record performance in the most recent quarter due to the company's shift in focus from contract manufacturing to producing biosimilars